JP2012502965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502965A5 JP2012502965A5 JP2011527395A JP2011527395A JP2012502965A5 JP 2012502965 A5 JP2012502965 A5 JP 2012502965A5 JP 2011527395 A JP2011527395 A JP 2011527395A JP 2011527395 A JP2011527395 A JP 2011527395A JP 2012502965 A5 JP2012502965 A5 JP 2012502965A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- cancer
- saturated aliphatic
- nfκb
- abnormal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 125000001931 aliphatic group Chemical group 0.000 claims 23
- 102000011727 Caspases Human genes 0.000 claims 16
- 108010076667 Caspases Proteins 0.000 claims 16
- 230000002159 abnormal effect Effects 0.000 claims 16
- 230000011664 signaling Effects 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 206010061218 Inflammation Diseases 0.000 claims 14
- 230000004054 inflammatory process Effects 0.000 claims 14
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 12
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 12
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 206010060862 Prostate cancer Diseases 0.000 claims 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 208000029742 colonic neoplasm Diseases 0.000 claims 8
- 230000006735 deficit Effects 0.000 claims 8
- 230000002779 inactivation Effects 0.000 claims 8
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 208000020084 Bone disease Diseases 0.000 claims 4
- 206010065687 Bone loss Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 208000027067 Paget disease of bone Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 210000000270 basal cell Anatomy 0.000 claims 4
- 208000016738 bone Paget disease Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000005787 hematologic cancer Diseases 0.000 claims 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- -1 piperidino, piperazino, morpholino, thiomorpholino Chemical group 0.000 claims 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010023203 Joint destruction Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000010029 ameloblastoma Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 210000003298 dental enamel Anatomy 0.000 claims 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CN(C)Cc1cc(NS(c(cc2)c(*)cc2-c(c(F)c2)ccc2F)(=O)=O)ccc1 Chemical compound CN(C)Cc1cc(NS(c(cc2)c(*)cc2-c(c(F)c2)ccc2F)(=O)=O)ccc1 0.000 description 2
- SUOMABXIKRAHEZ-UHFFFAOYSA-N Cc(c(CCO)ccc1)c1NS(c(cc1)ccc1-c(ccc(F)c1)c1F)(=O)=O Chemical compound Cc(c(CCO)ccc1)c1NS(c(cc1)ccc1-c(ccc(F)c1)c1F)(=O)=O SUOMABXIKRAHEZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9827508P | 2008-09-19 | 2008-09-19 | |
| US61/098,275 | 2008-09-19 | ||
| GB0817208.2 | 2008-09-19 | ||
| GBGB0817208.2A GB0817208D0 (en) | 2008-09-19 | 2008-09-19 | Therapeutic apsap compounds and their use |
| PCT/GB2009/002223 WO2010032010A1 (en) | 2008-09-19 | 2009-09-18 | Aryl-phenyl-sulfonamide-phenylene compounds and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502965A JP2012502965A (ja) | 2012-02-02 |
| JP2012502965A5 true JP2012502965A5 (enExample) | 2012-10-25 |
| JP5840492B2 JP5840492B2 (ja) | 2016-01-06 |
Family
ID=39951896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527395A Active JP5840492B2 (ja) | 2008-09-19 | 2009-09-18 | アリール−フェニル−スルホンアミド−フェニレン化合物とその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8207167B2 (enExample) |
| EP (1) | EP2349990B8 (enExample) |
| JP (1) | JP5840492B2 (enExample) |
| CA (1) | CA2736980C (enExample) |
| DK (1) | DK2349990T3 (enExample) |
| ES (1) | ES2675074T3 (enExample) |
| GB (1) | GB0817208D0 (enExample) |
| WO (1) | WO2010032010A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705400D0 (en) * | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| HK1211019A1 (en) * | 2012-12-10 | 2016-05-13 | F. Hoffmann-La Roche Ag | Benzyl sulfonamide derivatives as rorc modulators |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| LT3262028T (lt) * | 2014-12-17 | 2022-01-10 | Pimco 2664 Limited | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamido ir n-(-4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamido junginiai ir jų terapinis panaudojimas |
| JPWO2017170884A1 (ja) * | 2016-03-31 | 2019-02-14 | 富士フイルム富山化学株式会社 | 新規なヒドロキサム酸誘導体の製造方法およびその中間体 |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| GB201905520D0 (en) | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| EP4028384B1 (en) | 2019-09-12 | 2023-11-08 | BASF Agro B.V. | Process for the preparation of alpha-methyl-[4-(nitro)-2-(trifluoromethyl)]-benzyl nitrate |
| CA3191223A1 (en) | 2020-08-31 | 2022-03-03 | Alfonso Bellacosa | Methods of treating cancer |
| EP4431090A1 (en) | 2023-03-15 | 2024-09-18 | Istesso 1 Limited | Solfonamides acting as mitochondrial complex i modulator compounds |
| GB202308547D0 (en) | 2023-06-08 | 2023-07-26 | Istesso 2 Ltd | Tnf inhibitor combination therapies |
| GB202309515D0 (en) | 2023-06-23 | 2023-08-09 | Istesso 2 Ltd | JAK inhibitor and IL-6 inhibitor combination therapies |
| GB202315822D0 (en) | 2023-10-16 | 2023-11-29 | Istesso 3 Ltd | Anti-fibrotic combination therapeutics |
| GB202317050D0 (en) | 2023-11-07 | 2023-12-20 | Istesso 2 Ltd | Disease modifying anti-rheumatic drug combination therapies |
| GB202411554D0 (en) | 2024-08-06 | 2024-09-18 | Istesso 2 Ltd | NF-kB inhibitor combination therapies |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| US4119784A (en) * | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| GB2001307A (en) * | 1977-07-01 | 1979-01-31 | American Cyanamid Co | Sulphonamide blood complement inhibitors |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) * | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| CA2154103C (en) * | 1995-07-18 | 1998-02-24 | Samuel Simon Asculai | Treatment of mucous membrane disease, trauma or condition and for the relief of pain |
| CZ132798A3 (cs) | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Inhibitory proteázy |
| US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| EP0888344A1 (en) | 1996-03-15 | 1999-01-07 | The Du Pont Merck Pharmaceutical Company | Spirocycle integrin inhibitors |
| WO1998003166A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| AU734302B2 (en) | 1997-05-08 | 2001-06-07 | Smithkline Beecham Corporation | Protease inhibitors |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| PT877019E (pt) | 1997-05-09 | 2002-05-31 | Hoechst Ag | Acidos diaminocarboxilicos substituidos |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| JP2002501054A (ja) | 1998-01-23 | 2002-01-15 | アヴェンティス ファルマ ドイチェラント ゲーエムベーハー | 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体 |
| EP1053226A1 (en) | 1998-02-04 | 2000-11-22 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| DE19815547C1 (de) | 1998-04-07 | 1999-12-02 | Joachim Schmidt | Haftmittel für Zahnprothesen |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| CN1418210A (zh) * | 2000-03-21 | 2003-05-14 | 宝洁公司 | 含有碳环侧链的n－取代金属蛋白酶抑制剂 |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| NZ531153A (en) | 2001-08-09 | 2005-10-28 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| GB0126157D0 (en) | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| TW200305396A (en) | 2002-03-27 | 2003-11-01 | Shionogi & Co | Cartilage extracellular matrix degradation |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| DE10251170A1 (de) | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) * | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| ES2298753T3 (es) | 2003-05-07 | 2008-05-16 | The University Court Of The University Of Aberdeen | Cetonas y cetonas reducidas como agentes terapeuticos para el tratamiento de enfermedades oseas. |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| GB0324792D0 (en) * | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| BRPI0417687A (pt) | 2003-12-19 | 2007-04-03 | Pfizer | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| US20080255240A1 (en) | 2004-05-05 | 2008-10-16 | Novo Nordisk A/S | Sulfonamide Derivatives |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| EA200702498A1 (ru) | 2005-06-16 | 2008-06-30 | Пфайзер Инк. | N-(пиридин-2-ил)сульфонамидные производные |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| EA019879B1 (ru) * | 2005-12-29 | 2014-07-30 | Лексикон Фармасьютикалз, Инк. | Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
-
2008
- 2008-09-19 GB GBGB0817208.2A patent/GB0817208D0/en not_active Ceased
-
2009
- 2009-09-18 JP JP2011527395A patent/JP5840492B2/ja active Active
- 2009-09-18 WO PCT/GB2009/002223 patent/WO2010032010A1/en not_active Ceased
- 2009-09-18 DK DK09785123.2T patent/DK2349990T3/en active
- 2009-09-18 US US13/063,950 patent/US8207167B2/en active Active
- 2009-09-18 ES ES09785123.2T patent/ES2675074T3/es active Active
- 2009-09-18 EP EP09785123.2A patent/EP2349990B8/en active Active
- 2009-09-18 CA CA2736980A patent/CA2736980C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502964A5 (enExample) | ||
| HRP20150839T1 (hr) | Spojevi aril-fenil-sulfonamido-cikloalkila i njihova uporaba | |
| JP6721499B2 (ja) | 骨の成長を促進するためのアルキルアミンハルミン誘導体 | |
| CN101678014B (zh) | 杂环激酶调节剂 | |
| JP2024522373A5 (enExample) | ||
| CN119119176A (zh) | 喜树碱衍生物 | |
| JP2020508302A5 (enExample) | ||
| JP5840492B2 (ja) | アリール−フェニル−スルホンアミド−フェニレン化合物とその使用 | |
| KR20140010076A (ko) | 세포독성 벤조다이아제핀 유도체 | |
| JP2023515629A (ja) | Ｃｄｋ２／４／６阻害剤としての化合物 | |
| JP2013536807A5 (enExample) | ||
| BR112017027414B1 (pt) | Derivados hidroxiéster, processo para prepará-los e composições farmacêuticas os contendo | |
| CN110167941B (zh) | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 | |
| MX2010013699A (es) | Derivados de azacarbolinas, su preparacion y su uso terapeutico. | |
| JP5775304B2 (ja) | ガンの治療のためのイミダゾ［１，２−ａ］キノキサリンおよび誘導体 | |
| JP2016529218A5 (enExample) | ||
| CA2556768A1 (en) | Piperidinyl targeting compounds that selectively bind integrins | |
| WO2023040996A1 (zh) | 氮杂吲唑大环化合物及其用途 | |
| ES2450067T3 (es) | Derivados de pirido[2,3-d]pirimidina, proceso para su preparación y su uso terapéutico | |
| BR112019025866A2 (pt) | compostos e composições para indução de condrogênese | |
| CN114456180B (zh) | 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用 | |
| US20120095233A1 (en) | Kinase inhibitors | |
| AU2004298907B8 (en) | Use of a compound having two gold (I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (I) atoms for the treatment of cancer | |
| CN112135634A (zh) | 单磷酸吉西他滨的小分子药物偶联物 | |
| KR101932347B1 (ko) | 신규한 아조엔 유도체, 이의 제조방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |